Molecular Testing for Endometrial Cancer Remains Inconsistent Across Canada
A national survey reveals wide variation in how Canadian pathologists apply molecular classification for endometrial cancer, with resource gaps and unclear guidelines as key barriers.
Summary
Molecular classification of endometrial carcinoma has transformed how clinicians predict outcomes and tailor treatment, yet its adoption remains uneven. A survey of gynaecologic pathologists across 13 Canadian academic pathology departments found significant variability in how this classification is applied in practice. Key obstacles include limited laboratory resources and uncertainty about how molecular subtypes should guide clinical management. The authors argue that focused research, clearer guidelines, and better knowledge translation are essential to standardize implementation. This is particularly urgent given that multiple ongoing clinical trials are using molecular classification to test new treatment strategies and explore therapy de-escalation, meaning inconsistent testing could affect patient eligibility and outcomes.
Detailed Summary
Molecular classification of endometrial carcinoma represents one of the most significant advances in gynecologic oncology in recent years. By stratifying tumors into distinct molecular subtypes — including POLE-mutated, mismatch repair deficient, copy-number high, and copy-number low groups — clinicians can better predict prognosis and select appropriate therapies. This matters enormously as the field moves toward precision medicine and treatment de-escalation strategies.
To understand the current state of implementation in Canada, the authors distributed a digital survey to gynaecologic pathologists working in 13 academic pathology departments nationwide. The goal was to map both areas of consensus and divergence in how molecular classification is performed and interpreted across institutions.
The survey revealed meaningful variability in practice patterns. While some areas of homogeneity existed, significant differences emerged in testing workflows, subtype interpretation, and how results informed clinical decision-making. Pathologists identified two dominant barriers: resource constraints — including costs of sequencing and immunohistochemistry infrastructure — and ambiguity about how molecular subtype results should translate into management decisions.
The implications extend beyond routine diagnostics. Several active clinical trials are enrolling patients based on molecular subtype, testing whether certain low-risk subgroups can safely receive less aggressive treatment. Inconsistent molecular classification risks excluding eligible patients or misallocating therapies, undermining trial integrity and patient access to innovation.
The authors call for coordinated efforts in guideline development, knowledge translation, and targeted research to close these gaps. While the study is limited to Canadian academic centers and relies on self-reported survey data, it offers a timely snapshot of a system in transition and highlights the infrastructure investment needed to realize the full clinical value of endometrial cancer molecular classification.
Key Findings
- Survey of 13 Canadian academic pathology departments found significant variability in molecular classification practices for endometrial carcinoma.
- Resource limitations and unclear management guidelines were the top perceived barriers to universal adoption.
- Inconsistent molecular testing may affect patient eligibility for ongoing clinical trials testing treatment de-escalation.
- Some areas of practice homogeneity were identified, suggesting a foundation exists for standardization efforts.
- Authors recommend guideline development and knowledge translation as priority interventions.
Methodology
Cross-sectional digital survey distributed to gynaecologic pathologists across 13 Canadian academic pathology departments. The study identified areas of homogeneity and variability in molecular classification practice. No patient-level data were analyzed; findings reflect pathologist-reported institutional practices.
Study Limitations
Survey-based design relies on self-reported data, which may introduce response bias or inaccurate representation of actual practice. The study is limited to academic centers in Canada, potentially excluding community hospitals where gaps may be even larger. Only the abstract was available for analysis, limiting access to full survey methodology and quantitative results.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: